NBNoël J. C. Bauer

Noël J. C. Bauer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Noël J. C. Bauer has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: Artificial intelligence in pediatric myopia - a narrative review

    by Neelam Pawar, Tos T. J. M. Berendschot, Noël J. C. Bauer, R Meenakshi, Devendra Maheshwari, Binh Duong Giap, Nambi Nallasamy

  • Correction: Artificial intelligence in pediatric myopia—a narrative review

    by Neelam Pawar, Tos T. J. M. Berendschot, Noël J. C. Bauer, Meenakshi R, Devendra Maheshwari, Binh Duong Giap, Nambi Nallasamy

  • Open Access

    Artificial intelligence in pediatric myopia - a narrative review

    by Neelam Pawar, Tos T. J. M. Berendschot, Noël J. C. Bauer, Meenakshi R, Devendra Maheshwari, Binh Duong Giap, Nambi Nallasamy

    This review examines the promising potential of Artificial Intelligence (AI) in pediatric ophthalmology, specifically in the assessment, prediction, management, and treatment of myopia in children. The use of AI, particularly machine learning (ML) and deep learning (DL), in predicting myopia in children has garnered significant interest for its potential in early screening, detection, prognosis prediction, monitoring of anti-myopia treatment, personalized interventions, and proactive management strategies. This review aims to summarize the current literature on myopia and AI, presenting them as emerging trends and future directions in the pediatric population, and highlighting emerging strategies for the future of myopia management.


  • Open Access

    Six-month performance and safety of an iris-fixated multifocal intraocular lens for presbyopia correction in phakic eyes

    by Joukje C. Wanten, Julián Cezón, Rudy M.M.A. Nuijts, Juan A. Duran de la Colina, Mariano Royo, Chul Myong Choe, Jae Ho Choi, Chan Soo Park, Il Hwan Koh, Daniel Casado Rodríguez, et al.

    Purpose: To evaluate the 6-month effectiveness and safety of a new foldable multifocal iris-fixated phakic intraocular lens (pIOL) for presbyopia correction. Setting: Multicenter study at 7 sites. Design: Nonrandomized prospective clinical trial. Methods: Presbyopic patients without cataracts undergoing bilateral multifocal pIOL implantation (Ophtec ArtiPlus) were studied. The primary outcome for efficacy was the visual acuity at distance, intermediate, and near. Secondary outcomes included endothelial cell density (ECD), postoperative refraction, binocular defocus curve, vision quality, spectacle independence, and patient satisfaction. Results: 49 subjects (98 eyes) were included. At 6 months, the mean binocular uncorrected distance intermediate, and near visual acuity was −0.05 ± 0.09 logMAR, −0.02 ± 0.07 logMAR, and 0.02 ± 0.08 logMAR, respectively. The ECD remained stable with a mean value of 2771 ± 289 cells/mm 2 at 6 months postoperatively. The mean spherical equivalent was −0.42 ± 0.33 diopters (D), with 95% eyes having a prediction error within ±1.0 D and 77% within ±0.5 D. The binocular distance-corrected defocus curve showed a visual acuity of 0.20 logMAR or better over a range of +1.0 to −3.5 D. Patient satisfaction was high, with a mean score of 3.5 on a 4-point scale, and 83% of the patients reported spectacle independence. 47%, 35%, and 96% of patients reported experiencing glare, halos, and starbursts at well-tolerated levels, respectively. Notably, only 2% of patients found halos and starbursts to be very bothersome. Conclusions: Bilateral ArtiPlus multifocal pIOL implantation demonstrated good visual acuity from distant to near and maintained stable ECD over 6 months. Patients reported high levels of satisfaction and spectacle independence, despite some optical disturbances.


  • Open Access

    Optimizing the Postcataract Patient Journey Using AI-Driven Teleconsultation: Prospective Case Study

    by Joukje C Wanten, Noël J C Bauer, Mohita Chowdhury, Aisling Higham, Nick de Pennington, Frank J H M van Den Biggelaar, Rudy M M A Nuijts

    Background: Given the increasing global demand for ophthalmologic care and the anticipated shortage of ophthalmology professionals, innovative solutions are essential for optimizing health care delivery. Digital health technologies offer promising opportunities to efficiently manage high patient volumes. Cataract surgery, with its established safety profile and routine postoperative care, provides an ideal setting for implementing such innovations. Structured clinical questions have proven effective in identifying patients requiring further assessment, supporting the feasibility of follow-up through telephone consultations. To further extend this approach, artificial intelligence–based follow-up systems may offer an opportunity to automate these interactions, reduce clinician workload, and streamline care pathways. Objective: The aim of the study is to assess the clinical safety and effectiveness of an artificial intelligence–based follow-up call system (Dora-NL1) in identifying patients who require further assessment after cataract surgery in the Netherlands. Methods: This prospective single-center study was conducted at the University Eye Clinic Maastricht, the Netherlands. Adult patients who underwent uncomplicated cataract surgery were eligible to participate. All patients received a Dora-NL1 follow-up telephone call at 1 and 4 weeks postoperatively in addition to standard care (a clinician-led telephone consultation at week 1 and an in-person hospital visit at week 4). The Dora-NL1 calls used a standard conversational flow to evaluate symptoms and recommend a clinical outcome. The recommended outcomes of Dora-NL1 were based on the symptoms reported by the patient. Clinical safety and accuracy were assessed by comparing Dora-NL1 outcomes to blinded clinician assessments of recorded calls and to standard postoperative care. Patient-reported usability was measured using the Telehealth Usability Questionnaire and Net Promoter Score. Results: A total of 105 patients with a mean age of 72 (SD 7) years were included in the analysis. Dora-NL1 demonstrated high agreement with clinician-supervised calls, with symptom evaluation accuracy ranging from 89% to 99% (κ=0.390‐0.947) and care management decision accuracy between 83% and 88% (κ=0.640‐0.753). At week 1, Dora-NL1 showed a sensitivity of 100% and a specificity of 42% compared to standard clinician-led telephone consultations with no missed clinical concerns. At week 4, compared to the in-person follow-up, Dora-NL1 failed to identify 4 (4.1%) patients who required unexpected management changes, including 3 with asymptomatic complications detected only via slit lamp examination and 1 with complaints in the nonoperated eye. Patients rated Dora-NL1 positively, with Net Promoter Scores of +13.5 and +12.6 at week 1 and 4, respectively. The Telehealth Usability Questionnaire was completed by 98 patients, yielding a mean score of 3.19 (SD 1.13) on a 5-point scale, highlighting its simplicity, ease of use, and audibility. Conclusions: Dora-NL1 is a safe and effective tool for automated postoperative screening following cataract surgery. It offers a safe alternative to clinician-led telephone consultations in routine cases but cannot fully replace in-person examinations.

  • Open Access

    Efficacy of remote care in cataract surgery: systematic review

    by Joukje C. Wanten, Maartje H.M. Segers, Jos Kleijnen, Noël J.C. Bauer, Rudy M.M.A. Nuijts

    Topic: To evaluate the efficacy of currently available digital and remote care applications for postoperative cataract management compared with traditional methods for postoperative clinical measurements. Clinical Relevance: With the increasing demand for ophthalmological services and an anticipated shortage of professionals, innovative approaches are needed to optimize care. Cataract surgery, characterized by its high-safety profile and turnover rate, is well-suited for digital and remote care solutions, which could enhance the postoperative patient pathway, potentially leading to substantial time and cost savings. Methods: A systematic search was performed in Ovid Embase, Ovid MEDLINE, KSR Evidence, CINAHL, and Cochrane CENTRAL Library for randomized controlled trials (RCTs) and observational studies on digital tools, telemedicine, or remote care in postoperative cataract management. Reported outcomes included patient-reported outcomes, visual acuity, refraction, intraocular pressure, slitlamp and fundus examination, or complication prevalence. The risk of bias was evaluated using the Cochrane Risk-of-Bias Assessment Tool (v. 2) and Joanna Briggs Institute Critical appraisal checklists. Data extraction included both qualitative and quantitative information. The protocol was registered at International Prospective Register of Systematic Reviews (CRD42024505933). Results: The search identified 11 319 studies of which 14 were included. These comprised 4 RCTs and 10 observational studies involving 2681 patients. Interventions were categorized into telephone consultation, messaging, automated phone calls, and mobile applications/software. Telephone consultations were effective for follow-up screening, and automated phone calls also showed promising results. Messaging was suggested to improve adherence in the early postoperative period. Visual acuity assessment tools showed potential as screening methods, but exhibited variability compared with conventional methods and had wide 95% limits of agreement. All types of interventions were well-accepted by patients. Conclusions: Early evidence supports a positive impact of implementing digital and remote care tools in the postoperative cataract management pathway, particularly for screening purposes. However, further research is needed to define their roles and develop clinical practice guidelines.

  • Open Access

    A Novel Comparative Study of Inflammatory Cytokines Through Noninvasive Tear Analysis in Children With Myopia Versus Emmetropia

    by Shruti Nishanth, Noël J.C. Bauer, Rohit Shetty, Swaminathan Sethu, Arkasubhra Ghosh, Govindasamy Kumaramanickavel, Thiruchelvi S, Suvetha S, Marlies Gijs, Tos T.J.M. Berendschot


  • Open Access

    Dissatisfaction after implantation of EDOF intraocular lenses

    by Joukje C. Wanten, Noël J.C. Bauer, Tos T.J.M. Berendschot, Frank J.H.M. van Den Biggelaar, Rudy M.M.A. Nuijts

    Purpose: To evaluate the symptoms, etiology, and treatment of patient dissatisfaction after extended depth-of-focus (EDOF) intraocular lens (IOL) implantation. Setting: University Eye Clinic, Maastricht University Medical Center, the Netherlands. Design: Retrospective case series. Methods: For this study, all medical records of patients who received an EDOF IOL from July 2020 to July 2022 were reviewed. Patients were included if they had reported any dissatisfaction after surgery. The main outcome parameters were reasons for dissatisfaction (subjective complaints) and the presumed etiology of the complaints. Results: Of 202 patients (354 eyes) who underwent EDOF IOL implantation, 83 eyes (22.8%) of 52 dissatisfied patients were included. Blurred vision was the predominant complaint, reported in 78 eyes (94%). Photic phenomena were reported in 21 eyes (25.3%), with 16 eyes (76.2%) experiencing coexisting blurred vision. The major etiologies for dissatisfaction in this cohort were residual ametropia (51.8%), dry eye disease (26.5%), and posterior capsular opacification (12.0%). Treatments were administered to 85.5% of the eyes, including interventions such as artificial tears, spectacles, or refractive surgery enhancement. A small number of patients (n = 12; 5.9%) remained dissatisfied despite intervention. Conclusions: Based on this real-world data study, dissatisfaction after EDOF IOL implantation can be effectively identified and treated in most cases.


  • Open Access

    Two novel extended depth-of-focus intraocular lenses targeted for mini-monovision: A prospective randomized controlled trial

    by Joukje C. Wanten, Noël J.C. Bauer, Tos T.J.M. Berendschot, Frank J.H.M. van Den Biggelaar, Rudy M.M.A. Nuijts


  • Open Access

    A Retrospective, Nationwide, Multicenter Study on Diagnosis and Treatment Outcome of Pediatric Optic Pathway/Hypothalamic Gliomas Including Analysis of Risk Factors for Progression After Systemic Anticancer Therapy

    by Carlien A. M. Bennebroek, Judith van Zwol, Maartje C. Montauban van Swijndregt, Giorgio L. Porro, Rianne Oostenbrink, Anne T. M. Dittrich, Jan W. Pott, Lisethe Meijer, Etienne J. M. Janssen, Sylvia Klinkenberg, et al.

    Background: The current standard therapy for pediatric optic pathway/hypothalamic glioma (OPHG) is systemic anticancer therapy (SAT) over surgery and radiotherapy. Nevertheless, recurrent radiological or clinical tumor progression after SAT forms a considerable challenge. Sporadic OPHGs are considered to have a higher tendency toward progression after first-line systemic anticancer therapy (SAT) compared to neurofibromatosis type-1-associated (NF1) OPHGs. Methods: The objective of this study was to conduct a national retrospective cohort analysis of children who received various treatments for a progressive OPHG, involving the hypothalamus and/or chiasm and/or optic radiations. The study aimed to examine the differences in clinical course and the range of treatment modalities applied to both sporadic and NF1-associated OPHGs between 1995 and 2020. Additionally, we sought to identify risk factors for 3- and 5-year progression following first- and second-order SAT. Results: In total, 136 children received treatment, of whom 49 of 136 (36.0%) had NF1. Within a median of 7.5 years (range: 0.1–23.8 years) of follow-up, sporadic OPHGs received more treatments compared to NF1-associated OPHGs (median of 2 (range: 1–8) vs. median of 1 (range: 1–7) (p < 0.01)). Nine children with sporadic OPHGs (6.6%) died. Of 112 children (82.4%) receiving SAT, 92% received combined first-line vincristine and carboplatin. These children had a 3- and 5-year progression-free survival of 61.8% (95% CI: 51.0–72.6%) and 48.4% (95% CI: 38.0–58.8%), respectively. Sporadic OPHGs had a higher rate of second progression (p < 0.01). Starting first-line vincristine and carboplatin at an age below one year was the only independent risk factor for progression. Conclusions: In this national historic cohort of pediatric OPHGs, four out of five children received SAT. Sporadic OPHGs received a higher number of various SATs compared to NF1-associated OPHGs, but the sporadic appearance of OPHGs was not an independent risk factor for progression after combined vincristine and carboplatin, as ‘age below one year at the start’ was the only factor.